How could NIDA funding research into safer pain management drugs affect FDA?
DEA scheduling of SR-17018 complicates FDA's path for new pain drugs The discovery of SR-17018, a compound developed through NIDA-funded research, showed promise for relieving pain without causing respiratory depression or high tolerance. However, the US Drug Enforcement Administration emergency-scheduled the drug as a Schedule I controlled substance. This action, which makes it difficult to manufacture, ship, or touch, creates significant regulatory uncertainty. This uncertainty complicates the Food and Drug Administration's ability to conduct the necessary safety studies and evaluate the compound for potential human use.
- Effect
- Strong negative
- How direct
- Brind's reasoning
- When
- Over the long term
- The story
- Gone quiet
How it reaches FDA
-
Research funded by the National Institute on Drug Abuse identified compounds, including SR-17018, that can relieve pain in mice without causing respiratory depression. While the drug was previously available online and showed promise in resetting tolerance in opioid-dependent mice, clinical trials were halted after the US Drug Enforcement Admin took action against the compound.
The full event1independent outlet -
The discovery of SR-17018 was followed by the US Drug Enforcement Administration emergency-scheduling it as a Schedule I controlled substance. This regulatory move makes it much harder to conduct the clinical trials and safety studies that the Food and Drug Administration would need to evaluate the drug for human use.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- NIDA funded research that revealed compounds like SR-17018 could relieve pain in mice without causing respiratory depression.wired.com
- The US Drug Enforcement Administration emergency-scheduled SR-17018 as a Schedule I controlled substance in late August.wired.com
- The DEA notice of intent stated the four synthetic opioids have no currently approved medical use.wired.com
- The emergency scheduling will last two years, with a potential one-year extension.wired.com
Why it matters
The development of safer pain management drugs is critical given the opioid crisis, which began moving from prescription pills to heroin in 2012. Compounds like SR-17018 offer a potential off-ramp for addiction, as users reported it helped them quit opioids without experiencing physical withdrawal symptoms, unlike gold-standard drugs like buprenorphine and methadone.
This situation highlights the tension between public health needs and regulatory control. While scientists and advocates argue that SR-17018 has a lower risk profile and should be studied, the DEA's action is seen by some as potentially disrupting a multibillion-dollar industry, setting up a 'perfect storm for another overdose crisis.'
What we don't know yet
- Will the Food and Drug Administration be able to review the safety data for SR-17018 despite the DEA's scheduling?
- Will the DEA permanently schedule SR-17018 during the two-year emergency period?
What would change this answer
Reporting
- wired.comNov 3
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.